A cell‐penetrating CD40‐TRAF2,3 blocking peptide diminishes inflammation and neuronal loss after ischemia/reperfusion

• Published in: The FASEB journal Vol. 35; no. 3; pp. e21412 - n/a
• Main Authors: Portillo, Jose‐Andres C., Yu, Jin‐Sang, Hansen, Samuel, Kern, Timothy S., Subauste, M. Cecilia, Subauste, Carlos S.
• Format: Journal Article
• Language: English
• Published: United States John Wiley and Sons Inc 01-03-2021
• Subjects: Animals; CD40 Antigens - drug effects; CD40 Antigens - genetics; CD40 Antigens - metabolism; endothelial; Endothelial Cells - drug effects; Endothelial Cells - metabolism; Female; Humans; Inflammation - drug therapy; Inflammation - metabolism; Ischemia - drug therapy; Ischemia - metabolism; Male; Mice; muller cell; Neurons - cytology; Neurons - drug effects; Peptides - pharmacology; polymorphonuclear leukocyte; Reperfusion - methods; retina; Signal Transduction - drug effects; Signal Transduction - physiology; TNF Receptor-Associated Factor 2 - drug effects; TNF Receptor-Associated Factor 2 - metabolism; toxoplasma; muller cell; retina; polymorphonuclear leukocyte; endothelial; toxoplasma
• ISSN: 0892-6638; 1530-6860; 1530-6860
• DOI: 10.1096/fj.201903203RR

While the administration of anti‐CD154 mAbs in mice validated the CD40‐CD154 pathway as a target against inflammatory disorders, this approach caused thromboembolism in humans (unrelated to CD40 inhibition) and is expected to predispose to opportunistic infections. There is a need for alternative approaches to inhibit CD40 that avoid these complications. CD40 signals through TRAF2,3 and TRAF6‐binding sites. Given that CD40‐TRAF6 is the pathway that stimulates responses key for cell‐mediated immunity against opportunistic pathogens, we examined the effects of pharmacologic inhibition of CD40‐TRAF2,3 signaling. We used a model of ischemia/reperfusion (I/R)‐induced retinopathy, a CD40‐driven inflammatory disorder. Intravitreal administration of a cell‐penetrating CD40‐TRAF2,3 blocking peptide impaired ICAM‐1 upregulation in retinal endothelial cells and CXCL1 upregulation in endothelial and Müller cells. The peptide reduced leukocyte infiltration, upregulation of NOS2/COX‐2/TNF‐α/IL‐1β, and ameliorated neuronal loss, effects that mimic those observed after I/R in Cd40−/− mice. While a cell‐penetrating CD40‐TRAF6 blocking peptide also diminished I/R‐induced inflammation, this peptide (but not the CD40‐TRAF2,3 blocking peptide) impaired control of the opportunistic pathogen Toxoplasma gondii in the retina. Thus, inhibition of the CD40‐TRAF2,3 pathway is a novel and potent approach to reduce CD40‐induced inflammation, while likely diminishing the risk of opportunistic infections that would otherwise accompany CD40 inhibition.